Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease
Key Finding
Acetyl-L-carnitine produced significant cognitive improvements across 21 clinical trials, particularly in early-stage impairment.
Plain-English Summary
This meta-analysis examined 21 double-blind, placebo-controlled clinical trials of acetyl-L-carnitine (ALCAR) for cognitive impairment and Alzheimer's disease. Studies typically used 1.5-3g daily over 3-12 months.
ALCAR produced significant improvements in clinical measures across studies, with benefits appearing as early as 3 months and increasing over time. Improvements were observed in attention, memory, and verbal fluency. Effects were more pronounced in earlier-stage cognitive impairment.
ALCAR enhances mitochondrial energy production, supports acetylcholine synthesis, and has neuroprotective properties. It crosses the blood-brain barrier efficiently and provides both the acetyl group and carnitine moiety to neurons. ALCAR was well-tolerated with mild gastrointestinal effects being the most common complaint.